Protagenic Therapeutics, Inc.\new financial data

Symbol
PTIX, PTIXW on Nasdaq
Location
149 Fifth Avenue, Suite 500, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Atrinsic, Inc. (to 6/20/2016), NEW MOTION, INC. (to 6/30/2009), MPLC, Inc. (to 4/2/2007), MILLBROOK PRESS INC (to 5/23/2005)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 369 % -32.1%
Debt-to-equity 35.1 % +55.8%
Return On Assets -229 % -309%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.79M shares +53.2%
Common Stock, Shares, Outstanding 4.8M shares +10.9%
Entity Public Float 8.79M USD -29.7%
Common Stock, Value, Issued 481 USD +10.8%
Weighted Average Number of Shares Outstanding, Basic 4.53M shares +4.58%
Weighted Average Number of Shares Outstanding, Diluted 4.53M shares +4.58%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 4.16M USD +73.2%
General and Administrative Expense 1.22M USD -13.2%
Operating Income (Loss) -5.27M USD -32.7%
Nonoperating Income (Expense) -378K USD -943%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.65M USD -43.9%
Net Income (Loss) Attributable to Parent -5.65M USD -43.9%
Earnings Per Share, Basic -1.27 USD/shares -39.6%
Earnings Per Share, Diluted -1.27 USD/shares +56.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Marketable Securities, Current 1.59M USD -78.8%
Assets, Current 1.42M USD -73.5%
Property, Plant and Equipment, Net 85.6K USD +52.9%
Assets 1.51M USD -72.2%
Liabilities, Current 789K USD -38.3%
Liabilities 789K USD -38.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -130K USD +78.9%
Retained Earnings (Accumulated Deficit) -34.7M USD -19.4%
Stockholders' Equity Attributable to Parent 719K USD -82.7%
Liabilities and Equity 1.51M USD -72.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.66M USD -346%
Net Cash Provided by (Used in) Investing Activities 1.2M USD +308%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 4.8M shares +10.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -456K USD -495%
Deferred Tax Assets, Valuation Allowance 7.07M USD +27.2%
Deferred Tax Assets, Gross 7.07M USD +27.2%
Depreciation 64.3K USD +786%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.16M USD -31.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 35.6M USD +5.1%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 108K USD -21.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%